[go: up one dir, main page]

MA28435B1 - Composes d'indazole-carboxamide en tant qu'agonistes de recepteur 5-ht4 - Google Patents

Composes d'indazole-carboxamide en tant qu'agonistes de recepteur 5-ht4

Info

Publication number
MA28435B1
MA28435B1 MA29276A MA29276A MA28435B1 MA 28435 B1 MA28435 B1 MA 28435B1 MA 29276 A MA29276 A MA 29276A MA 29276 A MA29276 A MA 29276A MA 28435 B1 MA28435 B1 MA 28435B1
Authority
MA
Morocco
Prior art keywords
compounds
receptor agonists
carboxamide compounds
indazole
indazole carboxamide
Prior art date
Application number
MA29276A
Other languages
English (en)
Inventor
Daniel Marquess
Seok-Ki Choi
Paul R Fatheree
Roland Gendron
Adam A Goldblum
Daniel D Long
S Derek Turner
Jyanwei Liu
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34886184&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA28435(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of MA28435B1 publication Critical patent/MA28435B1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention a trait à des composés d'indazole-carboxamide agoniste de récepteur 5-HT4. L'invention a également trait à des compositions pharmaceutiques comprenant de tels composés, à des procédés d'utilisation de tels composés pour le traitement de maladies associées à l'activité de récepteur 5-HT4, et à des procédés et des intermédiaires utiles pour la préparation de tels composés.
MA29276A 2004-02-18 2006-08-18 Composes d'indazole-carboxamide en tant qu'agonistes de recepteur 5-ht4 MA28435B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US54570204P 2004-02-18 2004-02-18

Publications (1)

Publication Number Publication Date
MA28435B1 true MA28435B1 (fr) 2007-02-01

Family

ID=34886184

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29276A MA28435B1 (fr) 2004-02-18 2006-08-18 Composes d'indazole-carboxamide en tant qu'agonistes de recepteur 5-ht4

Country Status (16)

Country Link
US (3) US7351704B2 (fr)
EP (1) EP1718643A1 (fr)
JP (1) JP2007523175A (fr)
KR (1) KR20060132727A (fr)
CN (1) CN1922175A (fr)
AR (1) AR047681A1 (fr)
AU (1) AU2005214368A1 (fr)
BR (1) BRPI0507791A (fr)
CA (1) CA2553696A1 (fr)
IL (1) IL177059A0 (fr)
MA (1) MA28435B1 (fr)
NO (1) NO20064156L (fr)
RU (1) RU2006133320A (fr)
TW (1) TW200533348A (fr)
WO (1) WO2005080389A1 (fr)
ZA (1) ZA200606479B (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200533348A (en) * 2004-02-18 2005-10-16 Theravance Inc Indazole-carboxamide compounds as 5-ht4 receptor agonists
US7728006B2 (en) * 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
TWI351282B (en) 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
US8309575B2 (en) 2004-04-07 2012-11-13 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
EP1807422B1 (fr) * 2004-11-05 2009-09-02 Theravance, Inc. Composés antagonistes du récepteur 5-ht4
EP1807423B1 (fr) * 2004-11-05 2009-05-20 Theravance, Inc. Composes de quinolinone-carboxamide
RU2404179C2 (ru) * 2004-12-22 2010-11-20 Тереванс, Инк. Индазол-карбоксамидные соединения
TW200640921A (en) * 2005-02-17 2006-12-01 Theravance Inc Crystalline form of an indazole-carboxamide compound
WO2006094063A1 (fr) * 2005-03-02 2006-09-08 Theravance, Inc. Composes de quinolinone en tant qu’agonistes des recepteurs de 5-ht4
ES2359673T3 (es) * 2005-06-07 2011-05-25 Theravance, Inc. Compuestos de benzoimidazolona-carboxamida como agonista del receptor 5-ht4.
US20080262040A1 (en) * 2005-10-25 2008-10-23 Smithkline Beecham Corporation Chemical Compounds
MY143574A (en) * 2005-11-22 2011-05-31 Theravance Inc Carbamate compounds as 5-ht4 receptor agonists
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
WO2007097976A1 (fr) * 2006-02-16 2007-08-30 Theravance, Inc. Procédé pour préparer des intermédiaires de composés agonistes du récepteur 5-ht4
KR100812499B1 (ko) * 2006-10-16 2008-03-11 이도훈 항경련제
PT2121679E (pt) * 2007-02-23 2015-06-09 K H S Pharma Holding Gmbh Método para a produção de ésteres de azoniaspironortropina
WO2009101917A1 (fr) 2008-02-13 2009-08-20 Eisai R & D Management Co., Ltd. Dérivé de bicycloamine
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
WO2011092293A2 (fr) 2010-02-01 2011-08-04 Novartis Ag Dérivés de cyclohexylamide utilisés en tant qu'antagonistes du récepteur du crf
AR080055A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de los receptores de crf -1
ES2527849T3 (es) 2010-02-02 2015-01-30 Novartis Ag Derivados de ciclohexilamida como antagonistas del receptor de CRF
EP2533780B1 (fr) * 2010-02-12 2017-08-23 AskAt Inc. Agonistes du récepteur 5-ht4 pour le traitement de la démence
AR086554A1 (es) 2011-05-27 2014-01-08 Novartis Ag Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina
WO2012169649A1 (fr) * 2011-06-07 2012-12-13 Dainippon Sumitomo Pharma Co., Ltd. Dérivé d'indazole et pyrrolopyridine et utilisation pharmaceutique de celui-ci
MA20150428A1 (fr) 2012-05-03 2015-11-30 Novartis Ag Sel de l-malate de dérivés de 2,7-diaza-spiro[4.5]déc-7-yle et ses formes cristallines à titre d'agonistes des récepteurs de ghreline
JP2014133739A (ja) * 2012-12-12 2014-07-24 Dainippon Sumitomo Pharma Co Ltd インダゾール誘導体またはピロロピリジン誘導体からなる医薬
WO2016027277A1 (fr) * 2014-08-16 2016-02-25 Suven Life Sciences Limited Procédé de production à grande échelle d'oxalate de 1-isopropyl-3-{5-[1-(3-méthoxypropyl)pipéridin-4-yl]-[1,3,4]-oxadiazol-2-yl}-1h-indazole
CN112805282A (zh) * 2019-09-12 2021-05-14 广东东阳光药业有限公司 吲唑-甲酰胺衍生物及其用途

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4321378A (en) 1979-01-16 1982-03-23 Delalande S.A. 8-(5-Pyrimidinecarboxamide)nor-tropane derivatives
US4937247A (en) 1985-04-27 1990-06-26 Beecham Group P.L.C. 1-acyl indazoles
GB8527052D0 (en) * 1985-11-02 1985-12-04 Beecham Group Plc Compounds
NL8701682A (nl) 1986-07-30 1988-02-16 Sandoz Ag Werkwijze voor het therapeutisch toepassen van serotonine antagonisten, aktieve verbindingen en farmaceutische preparaten die deze verbindingen bevatten.
DE3777805D1 (de) 1986-11-21 1992-04-30 Glaxo Group Ltd Arzneimittel zur behandlung oder vorbeugung des entzugssyndromes.
GB8701022D0 (en) 1987-01-19 1987-02-18 Beecham Group Plc Treatment
US5223511A (en) 1987-09-23 1993-06-29 Boehringer Ingelheim Italia S.P.A. Benzimidazoline-2-oxo-1-carboxylic acid compounds useful as 5-HT receptor antagonists
IT1231413B (it) 1987-09-23 1991-12-04 Angeli Inst Spa Derivati dell'acido benzimidazolin-2-osso-1-carbossilico utili come antagonisti dei recettori 5-ht
IT1226389B (it) 1988-07-12 1991-01-15 Angeli Inst Spa Nuovi derivati ammidinici e guanidinici
NZ230068A (en) 1988-07-29 1991-07-26 Dainippon Pharmaceutical Co Indazole-3-carboxylic acid esters and amides of diaza compounds having 6,7, or 8 ring members: preparatory processes and pharmaceutical compositions
EP0410509A1 (fr) 1989-07-25 1991-01-30 Duphar International Research B.V Indazole-1H-carboxamides-3 substitués
JPH045289A (ja) 1990-04-24 1992-01-09 Hokuriku Seiyaku Co Ltd アミド化合物
JP3122671B2 (ja) 1990-05-23 2001-01-09 協和醗酵工業株式会社 複素環式化合物
HU211081B (en) 1990-12-18 1995-10-30 Sandoz Ag Process for producing indole derivatives as serotonin antagonists and pharmaceutical compositions containing the same
ES2080482T3 (es) 1990-12-28 1996-02-01 Kyowa Hakko Kogyo Kk Derivado de quinoleina.
AU2435092A (en) 1991-08-20 1993-03-16 Smithkline Beecham Plc 5-ht4 receptor antagonists
CA2118798A1 (fr) 1991-09-12 1993-03-18 Francis D. King Composes azabicycliques utilises comme antagonistes des recepteurs a 5-ht4
MX9305947A (es) 1992-09-29 1994-06-30 Smithkline Beecham Plc Compuestos antagonistas del receptor 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que las contienen.
US5571820A (en) 1992-11-20 1996-11-05 Taisho Pharmaceutical Co., Ltd. Heterocyclic compound
TW251287B (fr) 1993-04-30 1995-07-11 Nissei Co Ltd
GB9310582D0 (en) 1993-05-22 1993-07-07 Smithkline Beecham Plc Pharmaceuticals
AU679336B2 (en) 1994-02-28 1997-06-26 Taisho Pharmaceutical Co., Ltd. Heterocyclic compound
US5864039A (en) 1994-03-30 1999-01-26 Yoshitomi Pharmaceutical Industries, Ltd. Benzoic acid compounds and use thereof as medicaments
GB9406857D0 (en) 1994-04-07 1994-06-01 Sandoz Ltd Improvements in or relating to organic compounds
JP3829879B2 (ja) 1994-05-18 2006-10-04 大正製薬株式会社 キノリンカルボン酸誘導体
CA2160420A1 (fr) 1994-10-20 1996-04-21 Haruhiko Kikuchi Agonistes du recepteur 5-ht4
JP3829880B2 (ja) 1994-12-27 2006-10-04 大正製薬株式会社 化学中間体
IT1275903B1 (it) 1995-03-14 1997-10-24 Boehringer Ingelheim Italia Esteri e ammidi della 1,4-piperidina disostituita
US5654320A (en) 1995-03-16 1997-08-05 Eli Lilly And Company Indazolecarboxamides
CA2222532A1 (fr) 1995-05-31 1996-12-05 Nisshin Flour Milling Co., Ltd. Derives de l'indazole a groupe amino monocyclique
ES2109190B1 (es) 1996-03-22 1998-07-01 Univ Madrid Complutense Nuevos derivados de bencimidazol con afinidad por los receptores serotoninergicos 5-ht /5-ht
IT1291569B1 (it) 1997-04-15 1999-01-11 Angelini Ricerche Spa Indazolammidi come agenti serotoninergici
TW402591B (en) 1997-07-11 2000-08-21 Janssen Pharmaceutica Nv Monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
US5914405A (en) 1997-10-07 1999-06-22 Eli Lilly And Company Process for preparing 3-substituted indazoles
US6069152A (en) * 1997-10-07 2000-05-30 Eli Lilly And Company 5-HT4 agonists and antagonists
FR2769915B1 (fr) 1997-10-21 2000-10-13 Synthelabo Derives d'indazole tricycliques, leur preparation et leur application en therapeutique
IT1298271B1 (it) 1998-02-18 1999-12-20 Boehringer Ingelheim Italia Esteri ed ammidi dell'acido 2-oxo-2,3-diidro-benzimidazol-1- carbossilico
SK15852000A3 (sk) 1998-04-28 2001-06-11 Dainippon Pharmaceutical Co., Ltd. Derivát 1-[(1-substituovaného-4-piperidinyl)metyl]-4-piperidínu, spôsob jeho prípravy, farmaceutický prípravok obsahujúci tento derivát a medziprodukt tohto derivátu
KR100413150B1 (ko) 1998-09-10 2003-12-31 에프. 호프만-라 로슈 아게 5-에이치티4 수용체 길항제로서의 디하이드로벤조디옥신 카복스아미드 및 케톤 유도체
TW570920B (en) 1998-12-22 2004-01-11 Janssen Pharmaceutica Nv 4-(aminomethyl)-piperidine benzamides for treating gastrointestinal disorders
PE20001420A1 (es) 1998-12-23 2000-12-18 Pfizer Moduladores de ccr5
FR2792318B1 (fr) 1999-04-16 2001-06-15 Synthelabo Derives d'indazole, leur preparation et leur application en therapeutique
CN1461216A (zh) 1999-04-28 2003-12-10 呼吸器有限公司 用作治疗有关支气管收缩的机能障碍的药物的化合物
ES2154605B1 (es) 1999-09-14 2001-11-16 Univ Madrid Complutense Nuevos derivados mixtos de bencimidazol-arilpiperazina con afinidad por los receptores serotoninergicos 5-ht1a y 5-ht3
IT1313625B1 (it) 1999-09-22 2002-09-09 Boehringer Ingelheim Italia Derivati benzimidazolonici aventi affinita' mista per i recettori diserotonina e dopamina.
IT1313660B1 (it) 1999-10-01 2002-09-09 Dompe Spa Procedimento stereoselettivo per la preparazione di endo-3-amminoazabicicloalcani.
AU2002212888A1 (en) 2000-11-01 2002-05-15 Respiratorius Ab Composition comprising: serotonin receptor antagonists (5ht-2, 5ht-3) and agonist (5ht-4)
US6624162B2 (en) 2001-10-22 2003-09-23 Pfizer Inc. Imidazopyridine compounds as 5-HT4 receptor modulators
MXPA03000145A (es) 2002-01-07 2003-07-15 Pfizer Compuestos de oxo u oxi-piridina como moduladores de receptores 5-ht4.
CN1324025C (zh) 2002-04-08 2007-07-04 美国辉瑞有限公司 作为ccr5调节剂的托烷衍生物
US6696468B2 (en) 2002-05-16 2004-02-24 Dainippon Pharmaceutical Co., Ltd. (s)-4-amino-5-chloro-2-methoxy-n-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor
DOP2003000703A (es) 2002-09-20 2004-03-31 Pfizer Compuestos de imidazopiradina como agonistas del receptor 5-ht4
MXPA05003065A (es) 2002-09-20 2005-05-27 Pfizer Compuestos de piperidinil-imidazopiridina n-sustituidos como moduladores del receptor 5-ht4.
BRPI0409592A (pt) 2003-04-21 2006-05-02 Pfizer compostos imidazopiridina tendo atividade agonìstica do receptor 5-ht4 e atividade antagonìstica do receptor 5-ht3
JO2478B1 (en) 2003-06-19 2009-01-20 جانسين فارماسوتيكا ان. في. (Aminomethyl) -biperidine benzamides as 5 HT4 antagonists
PL1641783T3 (pl) 2003-06-19 2012-08-31 Janssen Pharmaceutica Nv 4-(aminometylo)-piperydyno-benzamidy podstawione aminosulfonylem jako antagoniści 5HT₄
DK1664036T3 (da) 2003-09-03 2012-02-13 Pfizer Benzimidazolonforbindelser med 5-HT4-receptoragonistisk virkning
US7964727B2 (en) 2003-11-24 2011-06-21 Pfizer Inc. Quinolonecarboxylic acid compounds having 5-HT4 receptor agonistic activity
CA2555258C (fr) 2004-01-29 2009-04-28 Pfizer Inc. Derives de 1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide presentant une activite agoniste du recepteur5-ht<sb>4</sb>
TW200533348A (en) * 2004-02-18 2005-10-16 Theravance Inc Indazole-carboxamide compounds as 5-ht4 receptor agonists
EP1807422B1 (fr) * 2004-11-05 2009-09-02 Theravance, Inc. Composés antagonistes du récepteur 5-ht4

Also Published As

Publication number Publication date
IL177059A0 (en) 2006-12-10
KR20060132727A (ko) 2006-12-21
NO20064156L (no) 2006-11-10
WO2005080389A1 (fr) 2005-09-01
CA2553696A1 (fr) 2005-09-01
US20050197335A1 (en) 2005-09-08
US8044045B2 (en) 2011-10-25
AU2005214368A1 (en) 2005-09-01
BRPI0507791A (pt) 2007-07-17
AR047681A1 (es) 2006-02-01
CN1922175A (zh) 2007-02-28
US20080146807A1 (en) 2008-06-19
TW200533348A (en) 2005-10-16
US7674908B2 (en) 2010-03-09
ZA200606479B (en) 2008-01-30
US20100261716A1 (en) 2010-10-14
RU2006133320A (ru) 2008-03-27
JP2007523175A (ja) 2007-08-16
EP1718643A1 (fr) 2006-11-08
US7351704B2 (en) 2008-04-01

Similar Documents

Publication Publication Date Title
MA28435B1 (fr) Composes d&#39;indazole-carboxamide en tant qu&#39;agonistes de recepteur 5-ht4
MA31764B1 (fr) Composés et compositions en tant que modulateurs de l&#39;activité de gpr119
MA28304A1 (fr) Derives d&#39;arylaniline utilise comme agonistes des recepteurs beta2-adrenergiques
MA28660B1 (fr) Composes et compositions en tant que modulateurs de ppar
MA33604B1 (fr) Composés et compositions en tant qu&#39;inhibiteurs de protéine kinase
MA31867B1 (fr) Agonistes nouveaux des recepteurs de glucocorticoides
MA30906B1 (fr) Composes et compositions en tant quinhibiteurs des proteines kinases
AP1542A (en) Glucocorticoid receptor modulators.
MA29568B1 (fr) Composes d&#39;azaindazole et methodes d&#39;utilisation desdits composes
MA30339B1 (fr) Azolopyrimidines inhibitrices de l&#39;activite du recepteur cannabinoïde 1
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.
MA38325A2 (fr) Dérivés de benzothiophène et compositions correspondantes en tant qu&#39;agents de dégradation sélectifs des récepteurs des œstrogènes
MA29550B1 (fr) Derives de n- (pyridine-2-yl) - sulfonamide
MA31087B1 (fr) Derives d&#39;amide et d&#39;ester d&#39;indazolyle pour traiter des troubles medies par le recepteur de glucocorticoïde.
MA31963B1 (fr) Composes antagonistes du recepteur du glucagon, compositions contenant de tels composes et procedes d&#39;utilisation
MA31283B1 (fr) Produits dérivés de 2,3-dihydroimidazo[1,2-c]quinazoline substitués, utiles pour le traitement de troubles hyperlifératifs et de maladies associées à une angiogénèse
MA31949B1 (fr) Dérivés d&#39;aminotriazole comme agonistes d&#39;alx
MY155036A (en) Quinolinone-carboxamide compounds as 5-ht4 receptor agonists
NO20073182L (no) Indazol-karboksamidforbindelser
TNSN08137A1 (fr) Derives de carboxamides servant d&#39;antagonistes des recepteurs muscariniques
TNSN01173A1 (fr) Compositions pharmaceutiques comprenant un antagoniste des recepteurs de nmda.
BR0104834A (pt) Moduladores de receptores de glucocorticóides
MA33419B1 (fr) Composés et compositions pour le traitement de maladies parasitaires
MA33132B1 (fr) Derives pyrazole utilises comme antagonistes du recepteur ccr4
MA31442B1 (fr) 3-(imidazolyl)-pyrazolo [3,4-b]pyridines